Dose Insider / Glossary / SNAC

SNACThe absorption enhancer that makes semaglutide tablets work

Updated November 20, 2026 · 3 min read · Rybelsus and Ozempic tablets label; Wegovy, Saxenda and Zepbound labels; Buckley 2018

SNAC, short for salcaprozate sodium, is an absorption enhancer: an inactive ingredient that helps another drug get into the body. It is the reason semaglutide can be taken as a tablet. Rybelsus tablets list it among their inactive ingredients with magnesium stearate, microcrystalline cellulose and povidone, and Ozempic tablets with magnesium stearate alone.

1% to 2%Semaglutide tablets with SNAC, Ozempic tablets, share of a dose in the blood
Share of a dose in the bloodAbsolute bioavailability, from the labelsINJECTIONSSemaglutide, Wegovy89%Tirzepatide, Zepbound80%Liraglutide, Saxenda55%SEMAGLUTIDE TABLETS WITH SNACOzempic tablets1% to 2%Rybelsus0.4% to 1%Share of a dose in the bloodAbsolute bioavailability, from the labelsINJECTIONSSemaglutide, Wegovy89%Tirzepatide, Zepbound80%Liraglutide, Saxenda55%SEMAGLUTIDE TABLETS WITH SNACOzempic tablets1% to 2%Rybelsus0.4% to 1%

Tablets rely on SNAC for the small share they deliver.

On this page

Both tablets contain it, and their label says SNAC facilitates the absorption of semaglutide after it is swallowed, mainly in the stomach.1

The problem it solves

Peptide drugs such as semaglutide are hard to give by mouth. A 2018 study by the drug's maker explains that they are poorly absorbed across the wall of the gut and are broken down by digestive enzymes. Its human and dog studies found that, unlike most pills, the semaglutide tablet is absorbed in the stomach, close to the surface of the tablet, and only when SNAC is in it.2

How it works

The same study reports that SNAC protects semaglutide from enzymes by buffering the area right around the tablet, and that it raises absorption only briefly. The semaglutide passes through the cells of the stomach lining, not between them, with no sign of an effect on the tight junctions that seal the gaps between cells. The authors found the mechanism specific to the compound, and say the findings show how peptide drugs could move from injections to tablets.2

How much gets in

Even with SNAC, very little of the tablet reaches the blood. The label puts the absolute bioavailability of semaglutide at about 0.4% to 1% for Rybelsus 3, 7 and 14 mg, and 1% to 2% for Ozempic tablets 1.5, 4 and 9 mg. Exposure rises in proportion to the dose. The highest level comes about 1 hour after the tablet, and a steady level is reached after 4 to 5 weeks of daily use.1 Injections do far better: 89% for semaglutide in Wegovy, 80% for tirzepatide and about 55% for liraglutide.3,4,5 The label adds that Rybelsus and Ozempic tablets are not interchangeable milligram for milligram.1

The Wegovy tablet

The Wegovy tablet for weight loss uses the same approach. Its label says the tablets are co-formulated with SNAC, that semaglutide is absorbed mainly in the stomach, and that about 1% to 2% of a dose reaches the blood, with the highest level 1 hour after the tablet. Like Rybelsus, it is taken once a day on an empty stomach in the morning, with up to 4 ounces of water.3

The label also notes a weakness of the tablet route. Semaglutide levels after Wegovy tablets were lower in people with type 2 diabetes, possibly because less was absorbed, and levels varied more from person to person than after the injection in every group studied. Some people with type 2 diabetes may therefore not reach effective levels, and for those who respond poorly the label suggests other treatments, including switching to the Wegovy injection.3

Why the tablet has strict rules

The label sets out strict rules for taking the tablets:1

Orforglipron, the GLP-1 in Foundayo, is a small molecule rather than a peptide and does not need SNAC; its label allows it to be taken without fasting.6 In rats, SNAC crossed the placenta and reached fetal tissue, which the tablet label reports in its pregnancy section.1

Sources

  1. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information. Novo Nordisk; DailyMed, version 14, published August 19, 2026; sections 2, 8.1, 11 and 12.3. dailymed.nlm.nih.gov
  2. Buckley ST, Bækdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med 2018;10:eaar7047. doi:10.1126/scitranslmed.aar7047
  3. WEGOVY (semaglutide) injection prescribing information. Novo Nordisk; DailyMed, version 19, published June 30, 2026; sections 2, 8 and 12.3. dailymed.nlm.nih.gov
  4. ZEPBOUND (tirzepatide) prescribing information, Medication Guide and Instructions for Use, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2.4, 5.6, 5.10, 6.1 and 12.3, Table 1. accessdata.fda.gov
  5. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version 22, published June 15, 2026; section 12.3. dailymed.nlm.nih.gov
  6. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, version published August 13, 2026; sections 11 and 12. dailymed.nlm.nih.gov

Related analyses

Log the time of each tablet and of your first food, so the 30-minute wait is easy to check.

Open Dose Insider